Methodological Issues in Preclinical Mouse Efficacy Studies of Adenomyosis

Sun‐Wei Guo
In: Current Obstetrics and Gynecology Reports · 2012 · vol. 1(3) , pp. 138–145 · doi:10.1007/s13669-012-0018-3 · W2056079194
article OA: hybrid CC0 ⤵ 2 in-corpus citations
📄 Open PDF View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-10 ⓘ

This systematic review evaluates the methodological quality and limitations of published mouse efficacy studies for adenomyosis treatments to improve future preclinical research.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-10 ⓘ

This paper systematically reviews all published preclinical mouse efficacy studies of adenomyosis that evaluated therapeutic compounds, using a PubMed search up to June 5, 2012 and focusing on methodological quality and limitations of the included studies. Across 14 initially identified rodent studies, only 10 met inclusion criteria, and the review highlights recurring issues such as induction-method confounding, strain dependence, long and variable adenomyosis induction periods, and potential underestimation of efficacy when vehicles like DMSO reduce adenomyosis induction success. A key caveat the author emphasizes is that translating these preclinical findings to clinical practice is challenged by poor alignment with what is actually being tested clinically, with few registered trials and no novel compounds in the public domain at the time. This paper is centrally about endometriosis and/or adenomyosis — it focuses on methodological issues in preclinical mouse efficacy studies specifically for adenomyosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Adenomyosis is a benign, non-neoplastic gynecologic disorder with a poorly understood pathogenesis. Its treatment has been a challenge, with hysterectomy being considered the definitive therapy for severe adenomyosis. More efficacious drugs with better side-effect and cost profiles are sorely needed. Unfortunately, there is a dearth of registered clinical trials on adenomyosis, and the registered trials are not testing new compounds. This appears to suggest a loss in translating discoveries made in preclinical studies to clinical practice. This article presents a systematic review of all published mouse efficacy studies of adenomyosis aimed at the evaluation of potential therapeutic compounds, focusing on methodological quality and describing the limitations of the published studies. The complex issues involved in translating preclinical studies to clinical practice will be summarized. Lastly, some methodological issues in mouse efficacy studies of adenomyosis will be highlighted, with the aim to improve such studies in the future.

My notes (saved in your browser only)

Condition tags

adenomyosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (71)

Cited by (2)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK